Medical Tai Chi Exercise Healing in Treating mCRC Patients

Inclusion Criteria:

1. Histological or cytological documentation of adenocarcinoma of the colon or rectum.
2. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2.
3. Life expectancy of at least 6 months.
4. Adequate bone marrow, liver, cardiac and renal function as assessed by the laboratoryrequired by protocol（ALT/AST≤2.5×UNL or ≤5×UNL with livermetastasis,TBIL≤2.5×UNL,Cr≤1.5×UNL,WBC≥3×109/L,NE≥1.5×109/L，PLT≥80×109/L，Hb≥90g/L,PT-INR/APTT <1.5UNL; LVEF≥ 50%）.
5. Subjects must complete the treatment and follow-up on schedule according to theresearch plan.

Exclusion Criteria:

1. Previous or concurrent cancer that is distinct in primary site or histology fromcolorectal cancer EXCEPT for curatively treated cervical cancer in situ, non-melanomaskin cancer and superficial bladder tumors [Ta (non-invasive tumor), Tis (carcinoma insitu) and T1 (tumor invades lamina propria)].
2. Any serious or unstable medical condition、mental illness or known active alcohol ordrug abuse or dependence.
3. Unhealed surgical wounds and intolerance
4. Extreme fatigue, anemia (<80 g/L) or dystaxia
5. toxicity grade ≥III in chemoradiotherapy or targeted therapy (NCI-CTCAE 5.0), orsevere intolerance
6. exercise contraindications for patients with cardiovascular diseases or pulmonarydiseases (referring to the Chinese Guideline for Cardiac Rehabilitation and SecondaryPrevention [edition 2018] and Evidence-based Practice Guidelines for ClinicalRehabilitation of Chronic obstructive Pulmonary Disease [edition 2021]); uncontrolledunstable angina, diastolic dysfunction grade IV, uncontrolled severe arrhythmia,uncontrolled hypertension;
7. high fever, serious infection, dyscrasia, multiple organ failure, or incapability tocooperate
8. thrombosis in the active phase
9. For female subjects: they should be surgical sterilized, postmenopausal patients, oragree to use a medically approved contraceptive method during the study treatmentperiod and within 6 months after the end of the study treatment period; The serum orurine pregnancy test must be negative within 7 days before enrollment and must be nonlactating. Male subjects: patients who agree to use a medically approved contraceptivemethod during the study treatment period and within 6 months after the end of thestudy treatment period.
10. other conditions confirmed by the multidisciplinary cancer rehabilitation team.